FGFR2 and urinary bladder cancer: Among patients with other tumor types who had genomic alterations, SD was attained by one patient with esophageal cancer and centrally assessed FGFR1 amplification, one patient with esophageal cancer and FGFR3 translocation, one patient with urothelial tract/bladder cancer and FGFR3 mutation (p.Y373C), one patient with breast cancer and FGFR2 amplification, and one patient with “other” (rectal cancer) and FGFR1 amplification.